THAI BIO LABS
฿500 OFF

Join the THAI BIO LABS Research Digest

Stay up to date with the latest published research and evidence on metabolic research peptides across our catalogue.

Enjoy an additional ฿500 off your first purchase of any metabolic research peptide. No minimum spend.

One email a month. Unsubscribe at any time.

สมัครรับข่าวสารงานวิจัยจาก THAI BIO LABS

Research Digest คือจดหมายข่าวรายเดือนที่รวบรวมงานวิจัยและหลักฐานที่เผยแพร่ล่าสุดเกี่ยวกับเปปไทด์กลุ่มเมตาบอลิกในแคตตาล็อกของเรา

รับส่วนลดเพิ่ม 500 บาท สำหรับการซื้อเปปไทด์สำหรับการวิจัยด้านเมตาบอลิซึมครั้งแรก โดยไม่มียอดซื้อขั้นต่ำ

รับอีเมลเดือนละ 1 ฉบับ ยกเลิกรับข่าวสารได้ทุกเมื่อ

One-time welcome offer. Bacteriostatic water excluded.

THAI BIO LABS
Menu × Close
Catalogue Batch Records Evidence Library Knowledge Center Calculator Quality Standards Cart (0)

Scientific Evidence Record · Growth & Hormonal

IPAMORELIN

A scientific record of the published literature, kept separate from THAI BIO LABS lot-level analytical documentation and commercial availability.

Selected sources checked: · Content version2.0 · AI-assisted screening; specialist review pending

Selected evidenceEarly human and laboratory studies
Supply contextResearch supply only
Review statusSpecialist review pending
Reading framework

Scope of this summary

Growth-hormone pharmacology · Postoperative gastrointestinal endpoints

Review contents

THAI BIO LABS scientific assessment

Evidence in context.

Key takeaways
  • Ipamorelin has laboratory growth-hormone research and a human postoperative study with an inconclusive primary efficacy comparison. These should not be presented as established benefits for body composition or recovery. [1][2]
  • A hormone response and a postoperative endpoint cannot be used interchangeably with muscle, sleep or general recovery claims.

Ipamorelin has laboratory growth-hormone research and a human postoperative study with an inconclusive primary efficacy comparison. These should not be presented as established benefits for body composition or recovery. [1][2]

Research overview

What the published record is evaluating.

The original pharmacology paper evaluated growth-hormone release in experimental systems. Hormone release is a mechanistic endpoint, not evidence of a long-term functional benefit. [1]

Selected studies

Findings and their limits.

Raun and colleagues described growth-hormone-releasing activity using laboratory and animal experiments in 1998. The design addresses pharmacology, not clinical body-composition outcomes. [1]

A 2014 phase 2 postoperative ileus study reported time to first tolerated meal of 25.3 versus 32.6 hours, with p=0.15. The numerical difference does not establish a statistically significant primary benefit. [2]

Primary research areas
  • Growth-hormone pharmacology
  • Postoperative gastrointestinal endpoints

Evidence quality

Strengths and limitations, shown together.

Strengths
  • The linked records make the study setting and measured endpoints checkable. They should be read with their design limitations.
Current limitations
  • A hormone response and a postoperative endpoint cannot be used interchangeably with muscle, sleep or general recovery claims.
  • This is a selected source summary, not a systematic review of all studies or a clinical recommendation.

Safety & tolerability evidence

Published safety context.

The selected studies do not establish the safety of a TBL research vial. Study-specific adverse-event reporting, formulation and follow-up must be assessed separately from analytical batch documentation.

Scientific outlook

Where the evidence may develop next.

Future updates should add identifiable primary studies, explain whether they change the conclusion, and retain relevant negative findings.

Selected references

Selected references from the published record.

These linked sources support the numbered statements above. This is a selected summary, not an exhaustive or independently signed-off systematic review. Sponsor announcements are labelled separately from published studies.

  1. Raun et al. Ipamorelin pharmacology, 1998. PMID 9849822. · Primary study
  2. Beck et al. Postoperative ileus study, 2014. PMID 25331030. · Primary study

INTERPRETATION FRAMEWORK

Different records. Different questions.

Three connected layers help interpret the evidence. They answer different questions and cannot substitute for one another.

Narrative Review

What the published scientific record reports, including its scope, findings and limitations.

Evidence Index

A structured reading framework. For metabolic peptides, it also preserves the original dated editorial scores and component breakdowns.

Batch Record

Analytical identity and other lot-specific documentation for a THAI BIO LABS material, when published.

Use the Evidence Index to examine the research interpretation and Batch Records to review documentation for a specific lot.

Research-use boundary

Clinical literature and THAI BIO LABS research materials are not the same record.

Published studies may concern approved medicines, investigational pharmaceutical material or other controlled research preparations. THAI BIO LABS materials are supplied for laboratory research use only and are not represented as medicines or substitutes for regulated pharmaceutical products.

LINE